Global expression of AMACR transcripts predicts risk for prostate cancer - a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate.

Saeid Alinezhad; Riina-Minna Väänänen; Natalia Tong Ochoa; Emily A Vertosick; Anders Bjartell; Peter J Boström; Pekka Taimen; Kim Pettersson

doi:10.1186/s12894-016-0128-8

Global expression of AMACR transcripts predicts risk for prostate cancer - a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate.

Saeid Alinezhad, Riina-Minna Väänänen, Natalia Tong Ochoa, Emily A Vertosick, Anders Bjartell, Peter J Boström, Pekka Taimen, Kim Pettersson

Skåne University Hospital

Research output: Contribution to journal › Article › peer-review

Abstract

The high false negative rates for initial prostate biopsies refer a large number of the men for repeat biopsies each year. Therefore, biomarkers associated with high risk of the presence of malignancy in histologically benign biopsies could provide a tool to discriminate the patients who need repeat biopsy or intensive follow-up from those who do not. Here we examined the diagnostic applicability of alpha-methylacyl CoA racemase (AMACR) and androgen receptor (AR) mRNA expression and AMACR protein levels in benign and cancerous prostatic tissue.

Original language	English
Article number	10
Journal	BMC Urology
Volume	16
Issue number	1
DOIs	https://doi.org/10.1186/s12894-016-0128-8
Publication status	Published - 2016

Subject classification (UKÄ)

Cancer and Oncology
Clinical Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/s12894-016-0128-8

http://www.ncbi.nlm.nih.gov/pubmed/26928323?dopt=Abstract

Cite this

Alinezhad, S., Väänänen, R.-M., Ochoa, N. T., Vertosick, E. A., Bjartell, A., Boström, P. J., Taimen, P., & Pettersson, K. (2016). Global expression of AMACR transcripts predicts risk for prostate cancer - a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate. BMC Urology, 16(1), Article 10. https://doi.org/10.1186/s12894-016-0128-8

@article{12887aa7afc44f76a047b69c03a80b32,

title = "Global expression of AMACR transcripts predicts risk for prostate cancer - a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate.",

abstract = "The high false negative rates for initial prostate biopsies refer a large number of the men for repeat biopsies each year. Therefore, biomarkers associated with high risk of the presence of malignancy in histologically benign biopsies could provide a tool to discriminate the patients who need repeat biopsy or intensive follow-up from those who do not. Here we examined the diagnostic applicability of alpha-methylacyl CoA racemase (AMACR) and androgen receptor (AR) mRNA expression and AMACR protein levels in benign and cancerous prostatic tissue.",

author = "Saeid Alinezhad and Riina-Minna V{\"a}{\"a}n{\"a}nen and Ochoa, {Natalia Tong} and Vertosick, {Emily A} and Anders Bjartell and Bostr{\"o}m, {Peter J} and Pekka Taimen and Kim Pettersson",

year = "2016",

doi = "10.1186/s12894-016-0128-8",

language = "English",

volume = "16",

journal = "BMC Urology",

issn = "1471-2490",

publisher = "BioMed Central (BMC)",

number = "1",

}

Alinezhad, S, Väänänen, R-M, Ochoa, NT, Vertosick, EA, Bjartell, A, Boström, PJ, Taimen, P & Pettersson, K 2016, 'Global expression of AMACR transcripts predicts risk for prostate cancer - a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate.', BMC Urology, vol. 16, no. 1, 10. https://doi.org/10.1186/s12894-016-0128-8

TY - JOUR

T1 - Global expression of AMACR transcripts predicts risk for prostate cancer - a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate.

AU - Alinezhad, Saeid

AU - Väänänen, Riina-Minna

AU - Ochoa, Natalia Tong

AU - Vertosick, Emily A

AU - Bjartell, Anders

AU - Boström, Peter J

AU - Taimen, Pekka

AU - Pettersson, Kim

PY - 2016

Y1 - 2016

N2 - The high false negative rates for initial prostate biopsies refer a large number of the men for repeat biopsies each year. Therefore, biomarkers associated with high risk of the presence of malignancy in histologically benign biopsies could provide a tool to discriminate the patients who need repeat biopsy or intensive follow-up from those who do not. Here we examined the diagnostic applicability of alpha-methylacyl CoA racemase (AMACR) and androgen receptor (AR) mRNA expression and AMACR protein levels in benign and cancerous prostatic tissue.

AB - The high false negative rates for initial prostate biopsies refer a large number of the men for repeat biopsies each year. Therefore, biomarkers associated with high risk of the presence of malignancy in histologically benign biopsies could provide a tool to discriminate the patients who need repeat biopsy or intensive follow-up from those who do not. Here we examined the diagnostic applicability of alpha-methylacyl CoA racemase (AMACR) and androgen receptor (AR) mRNA expression and AMACR protein levels in benign and cancerous prostatic tissue.

U2 - 10.1186/s12894-016-0128-8

DO - 10.1186/s12894-016-0128-8

M3 - Article

C2 - 26928323

SN - 1471-2490

VL - 16

JO - BMC Urology

JF - BMC Urology

IS - 1

M1 - 10

ER -

Global expression of AMACR transcripts predicts risk for prostate cancer - a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate.

Abstract

Subject classification (UKÄ)

UN SDGs

Access to Document

Fingerprint

Cite this